On July 29, 2026 Boston Scientific Corporation (NYSE: BSX) reported net sales of $5.442 billion during the second quarter of 2026, growing 7.5 percent on a reported basis and 7.0 percent on an operational1 and organic2 basis, all compared to the prior year period. The company reported GAAP net income attributable to Boston Scientific common stockholders of $907 million or $0.61 per share (EPS), compared to $797 million or $0.53 per share a year ago, and achieved adjusted3 EPS of $0.86 for the period, compared to $0.75 a year ago.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"Our team delivered a solid quarter while continuing to navigate a dynamic environment," said Mike Mahoney, chairman and chief executive officer, Boston Scientific. "We are focused on disciplined execution and prioritizing investments in our highest-impact opportunities, and we remain confident in Boston Scientific’s long-term growth, anchored by our category leadership strategy and our commitment to meaningful innovation for patients and physicians."
Second quarter financial results and recent developments:
Reported net sales of $5.442 billion, representing an increase of 7.5 percent on a reported basis, compared to the company’s guidance range of 5.5 to 7.5 percent; and 7.0 percent on an operational and organic basis, compared to the company’s guidance range of 5 to 7 percent, all compared to the prior year period.
Reported GAAP net income attributable to Boston Scientific common stockholders of $0.61 per share, and achieved adjusted EPS of $0.86 per share, compared to the guidance range of $0.82 to $0.84 per share.
Achieved the following net sales growth in each reportable segment, compared to the prior year period:
MedSurg: 5.9 percent reported, 5.4 percent operational and organic
Cardiovascular: 8.3 percent reported, 7.8 percent operational and organic
Achieved the following net sales growth in each region, compared to the prior year period:
United States (U.S.): 6.2 percent reported and operational
Europe, Middle East and Africa (EMEA): 6.1 percent reported and 4.2 percent operational
Asia-Pacific (APAC): 11.2 percent reported and operational
Latin America and Canada (LACA): 22.4 percent reported and 16.2 percent operational
Completed the previously announced $2 billion accelerated share repurchase program, repurchasing approximately 40 million shares.
Invested $1.5 billion in MiRus LLC, which is developing and commercializing proprietary biomaterials, implants and procedural solutions for the treatment of cardiovascular and orthopedic diseases, including the SIEGEL Balloon Expandable Transcatheter Aortic Valve Replacement (TAVR) system, in return for an approximately 34% equity stake and exclusive option to acquire the MiRus TAVR business.4
Presented late-breaking findings at EuroPCR from the FRACTURE Investigational Device Exemption trial, which met its primary endpoints with the SEISMIQ 4CE Coronary Intravascular Lithotripsy Catheter, demonstrating high rates of freedom from major adverse cardiac events at 30 days as well as procedural success in patients with severely calcified coronary artery disease.4
Announced clinical trial results that were presented in late-breaking sessions at Heart Rhythm 2026 including:
The AVANT GUARD study of FARAPULSE Pulsed Field Ablation (PFA) for the treatment of persistent atrial fibrillation (AF) in patients who had not previously been treated for their condition. Data met all safety and effectiveness endpoints and demonstrated statistical superiority of FARAPULSE PFA over anti-arrhythmic drugs with significantly higher primary effectiveness.
The ELEVATE-PF feasibility study of the FARAFLEX Mapping and PFA Catheter — a novel large focal, high-density map-and-ablate catheter — in patients with paroxysmal and persistent AF. The trial demonstrated strong lesion durability validated by cardiac remapping, with no reported cases of pulmonary vein stenosis, hemolysis, coronary spasm or clinical stroke.4
Commenced enrollment in the pivotal FARADIGM clinical trial to evaluate the safety and effectiveness of the FARAFLEX Mapping and PFA Catheter for treating patients with paroxysmal and persistent AF.4
Received U.S. Food and Drug Administration 510(k) clearance for the TruSelect 2.6 Microcatheter, expanding Boston Scientific’s embolization portfolio with a device designed to provide physicians with a single solution for navigation and efficient embolic delivery during minimally invasive procedures.
1.
Operational net sales growth excludes the impact of foreign currency fluctuations.
2.
Organic net sales growth excludes the impact of foreign currency fluctuations and net sales attributable to certain acquisitions and divestitures for which there are less than a full period of comparable net sales.
3.
Adjusted EPS excludes the impact of certain charges (credits) as defined below within the "Use of Non-GAAP Financial Measures" section.
4.
The SIEGEL Balloon Expandable TAVR system, the SEISMIQ 4CE Coronary Intravascular Lithotripsy Catheter and the FARAFLEX Mapping and PFA Catheter are investigational devices. Limited by Federal (or U.S.) law to investigational use only. Not available for sale.
Net sales for the second quarter by business and region:
View News Release Full Screen
Increase/(Decrease)
Three Months Ended
June 30,
Reported
Basis
Impact of
Foreign
Currency
Fluctuations
Operational
Basis
Impact of
Certain
Acquisitions
/Divestitures
Organic
Basis
(in millions)
2026
2025
Endoscopy
$ 793
$ 737
7.6 %
(0.7) %
7.0 %
— %
7.0 %
Urology
684
676
1.1 %
(0.3) %
0.8 %
— %
0.8 %
Neuromodulation
341
303
12.7 %
(0.6) %
12.2 %
— %
12.2 %
MedSurg
1,818
1,716
5.9 %
(0.5) %
5.4 %
— %
5.4 %
Cardiovascular
3,624
3,345
8.3 %
(0.6) %
7.8 %
— %
7.8 %
Net Sales
$ 5,442
$ 5,061
7.5 %
(0.5) %
7.0 %
— %
7.0 %
Increase/(Decrease)
Three Months Ended
June 30,
Reported
Basis
Impact of
Foreign
Currency
Fluctuations
Operational
Basis
(in millions)
2026
2025
U.S.
$ 3,426
$ 3,224
6.2 %
— %
6.2 %
EMEA
932
878
6.1 %
(1.9) %
4.2 %
APAC
878
790
11.2 %
(0.0) %
11.2 %
LACA
206
169
22.4 %
(6.2) %
16.2 %
Net Sales
$ 5,442
$ 5,061
7.5 %
(0.5) %
7.0 %
Amounts may not add due to rounding. Growth rates are based on actual, non-rounded amounts and may not recalculate precisely.
Net sales growth rates that exclude the impact of foreign currency fluctuations and/or the impact of certain acquisitions/divestitures are not
prepared in accordance with U.S. GAAP.
Guidance for Full Year and Third Quarter 2026
The company now estimates net sales growth for the full year 2026, versus the prior year period, to be approximately 5.5 to 6.5 percent on a reported basis and 5 to 6 percent on an organic basis. Full year organic net sales guidance excludes the impact of foreign currency fluctuations and net sales attributable to certain acquisitions and divestitures for which there are less than a full period of comparable net sales. The company now estimates adjusted EPS, excluding certain charges (credits), of $3.28 to $3.32.
The company estimates net sales growth for the third quarter of 2026, versus the prior year period, to be approximately 3 to 5 percent on a reported and organic basis. Third quarter organic net sales guidance excludes the impact of foreign currency fluctuations and net sales attributable to certain acquisitions and divestitures for which there are less than a full period of comparable net sales. The company estimates adjusted EPS, excluding certain charges (credits), of $0.80 to $0.82.
The company has not provided reconciliations of the forward-looking adjusted EPS guidance to GAAP guidance as it is unable to predict with reasonable certainty and without unreasonable efforts the impact of certain items such as intangible asset impairment charges, acquisition-related charges, restructuring and restructuring-related charges and litigation-related charges. The combined impact of these items is uncertain, dependent on various factors and cannot be predicted with reasonable certainty, and could be material to our GAAP measures of financial results.
Conference Call Information
Boston Scientific management will be discussing these results with analysts on a conference call today at 8:00 a.m. ET. The company will webcast the call to interested parties through its website: investors.bostonscientific.com. Please see the website for details on how to access the webcast. The webcast will be available for approximately one year on the Boston Scientific website.
(Press release, Boston Scientific, JUL 29, 2026, View Source [SID1234669487])